Bosutinib

證據等級: L5

預測適應症: 10 個

Bosutinib: From Philadelphia Chromosome-Positive Leukemia to Myeloid Leukemia

One-Sentence Summary

Bosutinib (Bosulif®) is a second-generation oral dual BCR-ABL/Src kinase inhibitor globally established as a standard-of-care treatment for Philadelphia chromosome-positive chronic myeloid leukemia (CML), but currently not registered in Taiwan. The TxGNN model predicts it may be effective for Myeloid Leukemia, with 3 completed Phase 3 trials and 20 publications directly supporting this indication — including the landmark BFORE trial confirming superiority over imatinib in newly diagnosed CML.

Quick Overview

Item	Content
Original Indication	Ph+ Chronic Myeloid Leukemia (globally approved; no Taiwan registration)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	98.75%
Evidence Level	L1
Taiwan Market Status	✗ Not Marketed
Number of Taiwan Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank was not retrieved in this evidence pack. Based on published pharmacological data, Bosutinib is a second-generation oral TKI that dually inhibits BCR-ABL kinase (including many imatinib-resistant kinase domain mutations) and Src family kinases (Src, Lyn, Hck). This dual inhibition simultaneously targets the primary oncogenic driver of CML — the constitutively active BCR-ABL fusion kinase arising from the t(9;22) Philadelphia chromosome translocation — and the downstream Src/Lyn-mediated proliferation and survival signals that amplify leukemic cell expansion.

Myeloid leukemia encompasses a disease spectrum unified by dysregulated myeloid progenitor proliferation. In Ph+ CML, BCR-ABL is the singular molecular driver, making Bosutinib’s kinase inhibition profile a mechanistically precise match for this disease. The TxGNN prediction for “myeloid leukemia” therefore reflects direct pharmacological congruence, not a speculative extrapolation. This is further reinforced by the ELN 2020/2025 clinical guidelines, which place Bosutinib as an equivalent first-line treatment option alongside imatinib, dasatinib, and nilotinib for newly diagnosed CML.

The key insight from this evaluation is not whether Bosutinib works for myeloid leukemia — three completed Phase 3 RCTs confirm it does — but rather that Taiwanese patients currently lack access to this established therapy due to the absence of a Taiwan TFDA registration. The TxGNN score of 98.75% reflects the model correctly identifying a globally proven indication, and the actionable finding is the regulatory gap that needs to be addressed.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02130557	Phase 3	Completed	536	BFORE: Bosutinib 400mg vs Imatinib 400mg in newly diagnosed CP-CML; demonstrated superior MMR (47.2% vs 36.9%) and CCyR at 12 months — primary pivotal trial supporting FDA/EMA approval
NCT00574873	Phase 3	Completed	502	Phase 3 RCT of Bosutinib vs Imatinib in newly diagnosed Ph+ CP-CML; assessed cytogenetic response at 1 year across international sites
NCT03106779	Phase 3	Completed	233	ASCEMBL: Asciminib vs Bosutinib 500mg in CML-CP after ≥2 prior TKIs; Bosutinib served as active control, establishing benchmark MMR rates in later-line settings
NCT05743465	N/A (RWE)	Completed	1769	Largest real-world comparative study of TKIs in CML; safety and clinical outcomes of Bosutinib, Ponatinib, Imatinib, Dasatinib, and Nilotinib in routine practice
NCT00261846	Phase 1/2	Completed	571	Seminal Bosutinib dose-escalation and efficacy study in Ph+ leukemias; established MTD and demonstrated broad activity across chronic, accelerated, and blast phases
NCT03885830	N/A (Observational)	Completed	45	Prospective TKI PK/PD exposure-response study in CP-CML; correlates Bosutinib clearance/exposure with clinical milestones, toxicity, and adherence
NCT03610971	Phase 2	Active, not recruiting	24	Ruxolitinib combined with TKI (including Bosutinib) to extend treatment-free remission in CP-CML relapsing after prior TKI discontinuation
NCT04793399	Phase 1/2	Terminated	9	Bosutinib + Atezolizumab combination in newly diagnosed CML; early safety signals evaluated before premature termination
NCT04258943	Phase 1/2	Active, not recruiting	60	ITCC-054/COG-AAML1921: Bosutinib in pediatric Ph+ CP-CML (newly diagnosed and resistant/intolerant); dose-finding and PK characterization in children
NCT02810990	Phase 2	Completed	65	BEST study: Bosutinib efficacy and tolerability in elderly CP-CML patients after front-line TKI failure; supports use in age-specific subpopulations

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29091516	2018	RCT (BFORE Phase 3)	J Clin Oncol	Bosutinib vs Imatinib in 536 newly diagnosed CP-CML patients; superior MMR and MCyR at 12 months; manageable GI and hepatic toxicity profile
35643868	2022	RCT (BFORE 5-year final)	Leukemia	5-year BFORE final analysis confirming durable molecular response superiority; 59.7% of bosutinib patients remained on study treatment at completion
34407542	2021	RCT (ASCEMBL Phase 3)	Blood	Phase 3 ASCEMBL: Asciminib vs Bosutinib 500mg in ≥2nd-line CML-CP; Bosutinib MMR ~25% at 24 weeks as active comparator benchmark
36717654	2023	RCT (ASCEMBL follow-up)	Leukemia	Extended ASCEMBL follow-up; Bosutinib comparator arm maintains consistent MMR rates confirming durable activity in multiply pretreated CML
32127639	2020	Guidelines (ELN 2020)	Leukemia	ELN 2020 recommendations: Bosutinib designated first-line CML treatment option with equivalent survival to other second-generation TKIs; favored for lower cardiovascular/metabolic risk
39093014	2024	Review (2025 update)	Am J Hematol	CML 2025 update: Bosutinib retained as standard first-line TKI; guidance on treatment sequencing, monitoring milestones, and treatment-free remission criteria
39252937	2024	Review (Bosutinib-focused)	Front Oncol	Comprehensive expert review of Bosutinib clinical data across all treatment lines; practical recommendations for patient selection and AE management
29695943	2018	Review	J Blood Med	Bosutinib patient selection and clinical perspectives; favorable cardiovascular profile (no vascular occlusion risk) distinguishes it from nilotinib/ponatinib
24711212	2014	Cohort (Phase 1/2)	Am J Hematol	Second-line Bosutinib after imatinib failure: 85% CHR, 59% MCyR at 24-month follow-up in 288 patients; confirmed activity across multiple resistance mechanisms
29773593	2018	Cohort (Phase 1/2 final)	Haematologica	5-year final results of second-line Bosutinib in CP-CML: 40% of patients remained on therapy at year 5; durable responses with predictable, manageable toxicity

Taiwan Market Information

Bosutinib currently has no marketing authorizations in Taiwan (0 registered products; TFDA status: 未上市). Despite FDA approval since 2012 and EMA approval (Bosulif®, Pfizer), Bosutinib remains inaccessible to Taiwanese CML patients through the domestic regulatory pathway.

Authorization	Product Name	Dosage Form	Approved Indication
—	—	—	No Taiwan TFDA authorizations registered

For prescribing reference, the global Bosulif® SmPC covers: Ph+ CML (chronic, accelerated, and blast phase) with prior TKI resistance or intolerance; newly diagnosed Ph+ CP-CML (FDA-approved 2017).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — BCR-ABL/Src tyrosine kinase inhibitor (second-generation TKI; not conventional cytotoxic)
Myelosuppression Risk	Moderate — Grade 3/4 thrombocytopenia occurs in 14–40% of patients; neutropenia and anemia also reported; distinct from alkylating agent-type pan-myelosuppression
Emetogenicity Classification	Low — GI toxicity predominantly manifests as diarrhea (dose-limiting in early treatment); nausea present but classical emesis uncommon; antiemetic prophylaxis generally not required
Monitoring Items	CBC with differential (monthly for first 3–6 months, then quarterly); hepatic transaminases ALT/AST (hepatotoxicity risk — monitor at baseline, then monthly for 3 months, then periodically); serum creatinine; BCR-ABL1 IS transcript monitoring per ELN milestones
Handling Protection	Standard oral TKI handling precautions — do not crush or split tablets; cytotoxic waste disposal protocols apply; pregnancy exposure prevention required

Safety Considerations

Taiwan TFDA prescribing information (SmPC) for Bosutinib is not currently available as the drug is not registered in Taiwan. Please refer to the Pfizer Bosulif® global SmPC and the FDA/EMA product labels for comprehensive information on warnings, contraindications, drug interactions, and special population guidance.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Bosutinib has the highest possible evidence grade (L1), supported by three completed Phase 3 RCTs (BFORE, NCT00574873, ASCEMBL), international guideline endorsement (ELN 2020/2025), and more than two decades of pharmacovigilance data — making this TxGNN prediction a validation of established clinical consensus rather than a speculative repurposing hypothesis. The barrier to patient access in Taiwan is regulatory, not evidentiary.

To proceed, the following is needed:

Taiwan TFDA NDA submission: Compile existing FDA/EMA clinical data package (clinical study reports from BFORE, NCT00574873, Phase 1/2 studies) for Taiwan registration application
Asian PK bridging assessment: The Japanese Phase 2 study (NCT03128411, n=64) provides Asian pharmacokinetic reference data; confirm whether TFDA requires additional Taiwan-specific PK bridging or accepts existing data
Full SmPC localization: Prepare Taiwan-language prescribing information covering safety warnings, contraindications (hepatic impairment dose adjustment, pregnancy/lactation exclusion), and DDI guidance (CYP3A4 interactions — pharmacokinetic study NCT02058277 provides aprepitant interaction data)
NHI reimbursement pathway: Initiate negotiation for inclusion in Taiwan National Health Insurance CML treatment coverage alongside established TKIs
Risk Management Plan: Establish monitoring protocols for myelosuppression (CBC), hepatotoxicity (LFTs), and GI toxicity management in line with ELN guidelines
Secondary indication scoping: After Taiwan CML registration, evaluate TxGNN rank-9 prediction for HER2-positive breast carcinoma (L2 evidence; Phase 1 trial NCT03854903 completed; two Phase 2 RCTs in ER+/HER2- BC) and rank-8 plasma cell myeloma (L4 preclinical evidence; Src/CAM-DR mechanistic rationale) as potential next-stage expansion indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.